Effects of glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in high-risk type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials
The approximately 380-hour half-life supports once-monthly dosing, which would be the longest dosing interval of any GLP-1 agonist
GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis
Diagnostic oxonium and y ions were used for spectral validation
President Trump last week hailed his deal with pharma companies to cut the price of blockbuster weight loss drugs as a major win for his administration and for increasing drug affordability
[DOI] [PubMed] [Google Scholar] 28.Bhatt D.L., Szarek M., Pitt B., Cannon C.P., Leiter L.A., McGuire D.K., Lewis J.B., Riddle M.C., Inzucchi S.E., Kosiborod M.N., et al